Covid-19: Jubilant Life Sciences launches generic version of remdesivir


PTI, Aug 4, 2020, 10:42 AM IST

Drug firm Jubilant Life Sciences on Monday, August 3 said it has launched the generic version of antiviral drug remdesivir in India for the treatment of Covid-19 patients.

The injectable drug, under the brand name ‘JUBI-R’, is priced at Rs 4,700 per vial of 100 mg.

The company will make the drug available to over 1,000 hospitals providing Covid-19 treatment, Jubilant Life Sciences said in a statement.

In order to increase the accessibility of the drug to patients below the poverty line and to front-line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organization of the Jubilant Group, is launching programs in India aimed at its distribution, it added.

“We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and in other countries,” Jubilant Pharma Chairman and MD Shyam S Bhartia and Co-Chairman Hari S Bhartia said in the statement.

The company’s ability to launch this product in such short timelines highlights “our R&D and manufacturing capabilities and our continued commitment to providing leading healthcare solutions”, they added.

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences Inc that granted it the right to register, manufacture and sell the US-based firm’s investigational drug remdesivir in 127 countries, including India, the statement said.

“On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe Covid-19,” it added.

“The drug will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner,” the statement said.

“Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) for the treatment of suspected or laboratory-confirmed Covid-19 in adults and children hospitalized with severe disease,” it added.

Shares of Jubilant Life Sciences closed at Rs 862.30 per scrip on BSE, up 8.42 percent from its previous close.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Activist Sarah Gill becomes Pakistan’s first transgender doctor

TN farmers take out anti-Mekedatu rally, slam Karnataka Cong for padayatra

Amit Palekar, AAP’s CM face in Goa, is lawyer and social worker, newcomer in politics

Over 40 cops from KSRP’s Mysuru battalion deployed for Cong Mekedatu march test COVID positive

M’luru: Physical classes to be cancelled in schools & colleges reporting 5 or more Covid cases: DC

5G scare: Air India cancels 8 US flights; DGCA working to overcome situation

Udupi: Woman killed in road accident at Brahmavar


Related Articles More

COVID-19 health emergency could be over this year, WHO says

Centre flags decline in Covid testing, asks states to enhance it

Go for test for TB, other conditions if cough persists for more than 2-3 weeks: Revised clinical guidance for Covid patients

K’taka govt warns medical professionals of action for spreading misinformation on Covid

Some COVID-19 patients may be infectious even after ten days: Study

MUST WATCH

Man Desighned Tallest Ridable Bicycle

Groundnut Cultivation Practices / Peanut farming in India

NEWS BULLETIN 19-01-2022

Crocodile and Dead Body found in Kali river Dandeli

Highlights of Sri Krishnapura Paryaya 2022


Latest Additions

Activist Sarah Gill becomes Pakistan’s first transgender doctor

TN farmers take out anti-Mekedatu rally, slam Karnataka Cong for padayatra

Amit Palekar, AAP’s CM face in Goa, is lawyer and social worker, newcomer in politics

Over 40 cops from KSRP’s Mysuru battalion deployed for Cong Mekedatu march test COVID positive

M’luru: Physical classes to be cancelled in schools & colleges reporting 5 or more Covid cases: DC

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.